JPEX America widens Japan-U.S. partnerships across healthcare and innovation

JPEX America said Aug. 20 it is expanding cross-border work linking Japan and the U.S. through business development, healthcare, investment and innovation. The Texas-based company also issued a clarification saying it has no affiliation with an unrelated cryptocurrency exchange that uses the JPEX name.

Why it matters: - JPEX America is trying to move beyond telecommunications and market-entry services into a broader cross-border platform for business development and innovation. - The expansion centers on Japan-Texas ties, with healthcare and life sciences positioned as a major growth area. - The company’s clarification aims to reduce confusion around its name and separate its work from an unrelated cryptocurrency exchange.

What happened: - JPEX America announced the continued expansion of its cross-border initiatives connecting corporations, startups, universities, healthcare institutions, investors and public-sector organizations in Japan and the United States. - The company is based in Texas and was founded by entrepreneur and angel investor Chihiro Shinzaki. - Shinzaki said the company’s goal is to build long-term relationships that can create new businesses, technologies and opportunities across both countries.

The details: - JPEX America said it has supported more than 100 Japanese companies with U.S. business activities. - The company said it has served more than 10,000 telecommunications customers. - JPEX America said it has built relationships across business, academia, healthcare, entrepreneurship, investment and government over more than a decade. - One of the company’s main initiatives is J-THINK, or Japan–Texas Healthcare Innovation Network. - J-THINK was co-founded to strengthen healthcare and life sciences connections between Japan and Texas. - The network connects researchers, entrepreneurs, universities, healthcare systems, corporations, investors and government organizations. - J-THINK is designed to create pathways for research collaboration, commercialization, investment and international market expansion. - JPEX America said Texas has become one of the U.S.’s most dynamic economic and innovation centers. - JPEX America said Japan contributes scientific research, healthcare expertise, advanced technologies and industry capabilities. - Shinzaki was born and raised in Tokyo, graduated from Keio University and studied at the University of California, Irvine as an exchange student. - Shinzaki said he is an active angel investor in healthcare, life sciences and technology startups, with interest in companies that can expand internationally. - The company published an official clarification on its website about the naming confusion. - JPEX America said it and Shinzaki have no affiliation with the cryptocurrency exchange known as JPEX. - The company said neither JPEX America nor Shinzaki has been involved in the exchange’s ownership, management, operations, investments, legal matters or business activities. - The official clarification is available as More information. - JPEX America’s website is the company’s website.

Between the lines: - JPEX America is pitching itself as a connector between ecosystems that already have complementary strengths, rather than as a single-market services firm. - The focus on healthcare, life sciences and investment suggests the company sees higher-value opportunities in sectors where cross-border partnerships can lead to research, funding and commercialization. - The name-clarification section shows the company is also managing reputation risk as it expands its profile.

What's next: - JPEX America said it plans to keep expanding across cross-border business development, strategic partnerships, healthcare innovation, entrepreneurship and investment. - The company said its long-term mission is to act as a trusted bridge between Japan and the United States and help organizations find partners and build sustainable opportunities. - Future growth will likely continue to center on Japan-Texas collaborations, especially in healthcare and innovation.